Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
8 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
NT 10-K
Notice of late annual filing
28 Feb 24
8-K
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
28 Feb 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8 Jan 24
8-K
Other Events
18 Dec 23
S-8
Registration of securities for employees
2 Nov 23
424B5
Prospectus supplement for primary offering
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Results of Operations and Financial Condition
2 Nov 23
8-K/A
Financial Statements and Exhibits
2 Nov 23
8-K
Other Events
17 Oct 23
S-3ASR
Automatic shelf registration
13 Oct 23
8-K
Other Events
13 Oct 23
8-K
Departure of Directors or Certain Officers
11 Sep 23
8-K
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
5 Sep 23
8-K
Departure of Directors or Certain Officers
30 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Results of Operations and Financial Condition
3 Aug 23
8-K
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
17 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Results of Operations and Financial Condition
4 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
17 Apr 23
8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
12 Apr 23
8-K
Departure of Directors or Certain Officers
6 Apr 23
8-K
Other Events
10 Mar 23
S-8
Registration of securities for employees
9 Mar 23
10-K
2022 FY
Annual report
8 Mar 23
8-K
Results of Operations and Financial Condition
8 Mar 23
8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
9 Jan 23
Latest ownership filings
4
ERIC BJERKHOLT
27 Mar 24
4
Peter Radovich
25 Mar 24
4
Peter Radovich
18 Mar 24
4
Pamela Vig
18 Mar 24
4
Lara Longpre
18 Mar 24
4
Christopher Peetz
18 Mar 24
4
ERIC BJERKHOLT
18 Mar 24
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
4
Pamela Vig
5 Feb 24
4
Lara Longpre
5 Feb 24
4
Peter Radovich
5 Feb 24
4
Christopher Peetz
5 Feb 24
4
Jolanda Howe
2 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
4
Pamela Vig
25 Jan 24
4
Lara Longpre
25 Jan 24
4
ERIC BJERKHOLT
25 Jan 24
4
Jolanda Howe
25 Jan 24
4
Peter Radovich
25 Jan 24
4
Christopher Peetz
25 Jan 24
4
Joanne Quan
18 Jan 24
3
Joanne Quan
18 Jan 24
4
Peter Radovich
9 Jan 24
4
Lara Longpre
9 Jan 24
4
Pamela Vig
9 Jan 24
4
Christopher Peetz
9 Jan 24
4
Jolanda Howe
9 Jan 24
SC 13D/A
New Enterprise Associates 16, L.P.
29 Dec 23
4
Jolanda Howe
6 Dec 23
4
Pamela Vig
15 Nov 23
4
Lara Longpre
15 Nov 23
4
Peter Radovich
15 Nov 23
4
Patrick J Heron
14 Nov 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
18 Sep 23
4
Patrick J Heron
15 Sep 23
4
MICHAEL G GREY
14 Sep 23
144
Notice of proposed sale of securities
14 Sep 23
4
Patrick J Heron
13 Sep 23
4
ERIC BJERKHOLT
12 Sep 23